878 results on '"Kawaoka, Yoshihiro"'
Search Results
2. A compendium of multi-omics data illuminating host responses to lethal human virus infections
3. Attenuation of A(H7N9) influenza virus infection in mice exposed to cigarette smoke
4. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
5. Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine
6. Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV
7. An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants
8. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
9. Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial
10. Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals
11. Host range, transmissibility and antigenicity of a pangolin coronavirus
12. Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses
13. Glyco-engineered MDCK cells display preferred receptors of H3N2 influenza absent in eggs used for vaccines
14. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
15. Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
16. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
17. Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2
18. Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection
19. Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge
20. Tracing the origin of SARS-CoV-2 omicron-like spike sequences detected in an urban sewershed: a targeted, longitudinal surveillance study of a cryptic wastewater lineage
21. Assessment of the antigenic evolution of a clade 6B.1 human H1N1pdm influenza virus revealed differences between ferret and human convalescent sera
22. Characterization of a human H3N8 influenza virus
23. Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan
24. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
25. Isolation of Bat Sarbecoviruses, Japan
26. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022
27. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents
28. Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination
29. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
30. Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents
31. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters
32. High titers of infectious SARS-CoV-2 in corpses of patients with COVID-19
33. Multi-omics of NET formation and correlations with CNDP1, PSPB, and L-cystine levels in severe and mild COVID-19 infections
34. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters
35. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2
36. COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions
37. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
38. Characterization of a new SARS-CoV-2 variant that emerged in Brazil
39. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
40. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
41. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
42. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
43. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
44. Sialylated and sulfated N-Glycans in MDCK and engineered MDCK cells for influenza virus studies
45. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
46. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
47. Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
48. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2
49. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
50. Establishment of human airway epithelial cells with doxycycline-inducible cell growth and fluorescence reporters
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.